Search Results - "Kaila, Shuchita"

Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States by Medhekar, Rohan, Ran, Tao, Fu, Alex Z, Patel, Sharmila, Kaila, Shuchita

“…Abstract Background There is limited real-world evidence that describes patients with newly diagnosed multiple myeloma (NDMM) treated with the bortezomib,…”
Get full text

Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study by Atrash, Shebli, Thompson-Leduc, Philippe, Tai, Ming-Hui, Kaila, Shuchita, Gray, Kathleen, Ghelerter, Isabelle, Lafeuille, Marie-Hélène, Lefebvre, Patrick, Rossi, Adriana

“…Daratumumab, a CD38 monoclonal antibody, has demonstrated efficacy as monotherapy and combination therapy across several indications, both among…”
Get full text

Correction to: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study by Atrash, Shebli, Thompson-Leduc, Philippe, Tai, Ming-Hui, Kaila, Shuchita, Gray, Kathleen, Ghelerter, Isabelle, Lafeuille, Marie-Hélène, Lefebvre, Patrick, Rossi, Adriana

Get full text

Comparison of Time to Next Treatment or Death Between Front‐Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant‐Ineligible Patients With Multiple Myeloma by Hansen, Doris K., Gautam, Santosh, Lafeuille, Marie‐Hélène, Rossi, Carmine, Moore, Bronwyn, Tardif‐Samson, Anabelle, Thompson‐Leduc, Philippe, Fu, Alex Z., Cortoos, Annelore, Kaila, Shuchita, Fonseca, Rafael

“…ABSTRACT Introduction Daratumumab, lenalidomide, and dexamethasone (DRd) and bortezomib, lenalidomide, and dexamethasone (VRd) are the only preferred treatment…”
Get full text

PB2110: PREDICTORS OF FRONTLINE (FL) DOUBLET OR TRIPLET REGIMEN USE AMONG TRANSPLANT‐INELIGIBLE (TIE) PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) USING A MACHINE LEARNING APPROACH by Pianko, Matthew J., Gupta‐Werner, Niodita, Emond, Bruno, Lefebvre, Patrick, Lafeuille, Marie‐Helene, Cortoos, Annelore, Kaila, Shuchita

Get full text

Real-world Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States by Fonseca, Rafael, Chinaeke, Eric E., Gupta-Werner, Niodita, Fu, Alex Z., Kaila, Shuchita

“…Daratumumab (DARA) is an anti-CD38 monoclonal antibody approved as a combination therapy for newly diagnosed multiple myeloma (MM) and as monotherapy and…”
Get full text

P1685: PATIENTS’ PREFERENCES FOR MULTIPLE MYELOMA (MM) TREATMENT INITIATION AND DISCONTINUATION IN THE US by Binder, Adam F., Shah, Urvi A., Gupta‐Werner, Niodita, Lu, Hui, Venkatraman, Malavika, Whitty, Jennifer, Khare, Vipin, Costa, Olivia, Kaila, Shuchita, Lipe, Brea C.

Get full text

PB2128: CLINICAL CONSENSUS ON FIRST‐LINE (1L) TREATMENTS FOR TRANSPLANT‐INELIGIBLE (TIE) PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): DELPHI PANEL OF US HEMATOLOGISTS AND ONCOLOGISTS by Fonseca, Rafael, Rossi, Adriana, Voelker, Jennifer, Homan, Trevor, Kaila, Shuchita, Medhekar, Rohan, Wilcock, Jessica, Karakusevic, Anna, Cochrane, James, Bridge, Daisy, Perry, Richard, Davies, Faith E

Get full text

Factors associated with dose adjustment for the bortezomib, lenalidomide, dexamethasone regimen among patients with newly diagnosed multiple myeloma by Ran, Tao, Medhekar, Rohan, Fu, Alex Z., Patel, Sharmila, Kaila, Shuchita

“…8039 Background: VRd (bortezomib/lenalidomide/dexamethasone) has become one of the established treatment regimens in the US for multiple myeloma (MM). Due to…”
Get full text

EVALUATION OF THE IMPACT OF A PATIENT SUPPORT PROGRAM FOR IDIOPATHIC PULMONARY FIBROSIS ON MEDICATION PERSISTENCE by Kaila, Shuchita, Near, Aimee, Burudpakdee, Chakkarin, Viswanathan, Shilpa

Get full text

Adjusted indirect treatment comparison of progression-free survival (PFS) associated with DRd and VRd based on MAIA and SWOG S0777 individual patient-level data by Durie, Brian G., Kumar, Shaji, Ammann, Eric M., Fu, Alex Z., Kaila, Shuchita, Lam, Annette, Usmani, Saad Zafar, Facon, Thierry

“…8037 Background: Both daratumumab in combination with lenalidomide and dexamethasone (DRd) and bortezomib in combination with lenalidomide and dexamethasone…”
Get full text

Characteristics and Outcomes of Non-Transplanted Patients with Newly Diagnosed Multiple Myeloma (NDMM) Initiating Treatment with Bortezomib, Lenalidomide, and Dexamethasone (VRd) As First-Line of Therapy by Medhekar, Rohan, Ran, Tao, Fu, Alex Z., Patel, Sharmila, Kaila, Shuchita

“…Introduction: In the US, bortezomib, lenalidomide, and dexamethasone (VRd) is one of the preferred treatment regimens in transplant-ineligible patients with…”
Get full text

Real-World Patient Characteristics and Treatment Outcomes Among Newly Diagnosed Multiple Myeloma Patients Initiating Daratumumab, Lenalidomide, and Dexamethasone As First-Line Therapy by Tai, Ming-Hui, Cai, Qian, Fu, Alex Z., Khare, Vipin, Kaila, Shuchita

“…Introduction: Daratumumab, a CD38 monoclonal antibody, was approved for the treatment of heavily pretreated relapsed or refractory multiple myeloma (MM) in…”
Get full text

Characteristics and Treatment of Patients with Multiple Myeloma Who Received Daratumumab in a Large Claims Database in the United States by Feng, Snow X, Fu, Alex Z., Khare, Vipin, Ogbonnaya, Augustina, Kaila, Shuchita

“…Introduction: Daratumumab (DARA) is a human IgGk monoclonal antibody targeting CD38 with a direct on-tumor and immunomodulatory mechanism of action. Since its…”
Get full text

Impact of cancer- and patient-level factors on provider risk in the Oncology Care Model by Chaudhry, Basit Iqbal, Yue, Andrew, Kaila, Shuchita, Sadik, Kay, Tran, Lisa, Connor, Nora

“…Abstract only e18852 Background: Transferring financial risk from payers to providers to align incentives is central to value-based payment (VBP) reform,…”
Get full text

MM-318 Perspectives of Single-Center Community Hematologists/Oncologists on Minimal Residual Disease Testing Among Patients With Multiple Myeloma by Gordan, Lucio N., Warner, Amanda, Heritage, Trevor, Ming, Amy, Gupta-Werner, Niodita, Kaila, Shuchita, Cortoos, Annelore

“…Minimal residual disease (MRD) testing in multiple myeloma (MM) is important for monitoring remission status and relapse. MRD negativity is an independent…”
Get full text

P-170 Perspectives of Single-Center Community Hematologists/Oncologists on Minimal Residual Disease Testing Among Patients With Multiple Myeloma by Gordan, Lucio, Warner, Amanda, Heritage, Trevor, Ming, Amy, Gupta-Werner, Niodita, Kaila, Shuchita, Cortoos, Annelore

Get full text

Perspectives of Single-Center Community Hematologists/Oncologists on Minimal Residual Disease Testing Among Patients With Multiple Myeloma by Gordan, Lucio N., Warner, Amanda, Heritage, Trevor, Ming, Amy, Gupta-Werner, Niodita, Kaila, Shuchita, Cortoos, Annelore

Get full text

Real-world healthcare resource utilization and costs among patients with multiple myeloma in the United States by Gupta, Niodita, Tai, Ming-Hui, Kaila, Shuchita, Thompson-Leduc, Philippe, Ghelerter, Isabelle, Kurteva, Siyana, Lefebvre, Patrick, Lafeuille, Marie-Hélène

“…e18811 Background: The economic burden of multiple myeloma (MM) has been shown to increase with more advanced lines of therapy (LOTs). Given the rapidly…”
Get full text

Systematic Literature Review and Meta-Analysis of Comparative Clinical Evidence Investigating Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) As First-Line Treatment for Transplant-Ineligible Newly Diagnosed Multiple Myeloma by Gordan, Lucio, Medhekar, Rohan, Fu, Alex Z., Ramirez, Abril Oliva, Bonar, Nicolle, Nguyen, Bao-Ngoc, Spence, Michaela, McTavish, Rebecca, Disher, Tim, Kaila, Shuchita, Patel, Anjan J.

“…Background: Daratumumab in combination with lenalidomide and dexamethasone (DRd) and bortezomib in combination with lenalidomide and dexamethasone (VRd) are…”
Get full text